vimarsana.com

Page 66 - தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Detecting Prostate Cancer With Advanced Micro-ultrasound

Detecting Prostate Cancer With Advanced Micro-ultrasound A new imaging choice for patients considering MRI MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging Visualization and targeting of a guided prostate biopsy using the ExactVu micro-ultrasound at a small Gleason 8 lesion. The small hypoechoic lesion is 0.49 cm x 0.61 cm (0.19” x 0.24”) in size. Biopsy was verified by clinical pathology. Image courtesy of Exact Imaging Brian Wodlinger, Ph.D. Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next step a prostate biopsy to determine if the increased PSA level was due to cancer or another condition such as infection or benign prostatic hyperplasia. These biopsies were performed using s

Not Just BRCA: Large Studies ID Other Key Breast Cancer Risk Genes

email article Two large breast cancer case-control studies of women from the United States, Europe, and Asia identified eight genes that had significant associations with breast cancer risk BRCA1, BRCA2, PALB2, ARD1, RAD51C, RAD51D, ATM, and CHEK2. Both studies were published in the New England Journal of Medicine. The first, by Fergus J. Couch, PhD, of the Mayo Clinic in Rochester, Minnesota, and colleagues, looked at a panel of 28 cancer-predisposition genes in approximately 64,000 women from the United States (32,247 with breast cancer). The team analyzed germline pathogenic variants using data from women in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium and found pathogenic variants in 12 established breast cancer predisposition genes in 5.03% of women with breast cancer compared with 1.63% of controls.

ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer

Press release content from Business Wire. The AP news staff was not involved in its creation. ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer January 20, 2021 GMT Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens. In Europe, approximately 531,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive. 1,2,3 The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths per year in Europe. 1

Cancer Surgery Mortality Down, but Racial Disparities Persist

Cancer Surgery Mortality Down, but Racial Disparities Persist
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Aldeyra Therapeutics (NASDAQ:ALDX), ConAgra Foods, Inc (NYSE:CAG) - Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity

Aldeyra Therapeutics (NASDAQ:ALDX), ConAgra Foods, Inc (NYSE:CAG) - Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.